Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Patient Preference 1Leiomyoma 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1Agnosia 1

Interventions

Cyclophosphamide 908Carboplatin 785Paclitaxel 739pembrolizumab 738Cisplatin 707Bevacizumab 705Gemcitabine 619Docetaxel 578Rituximab 548Radiotherapy 539Dexamethasone 510Nivolumab 485Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 357Pemetrexed 334Cytarabine 334Oxaliplatin 333Lenalidomide 327Prednisone 326fludarabine phosphate 315Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × Injections, Subcutaneous × Clear all
NCT05415215 2026-02-10

ProHer

Hoffmann-La Roche

Phase 3 Completed
346 enrolled 20 charts
Breast

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT02270255 2019-08-14

Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization

McGill University Health Centre/Research Institute of the McGill University Health Centre

Phase 2 Completed
44 enrolled 8 charts

Agnosia, Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡